Show simple item record

dc.creatorKalligeros, Markos
dc.creatorShehadeh, Fadi
dc.creatorAtalla, Eleftheria
dc.creatorMylona, Evangelia K.
dc.creatorAung, Su
dc.creatorPandita, Aakriti
dc.creatorLarkin, Jerry
dc.creatorSanchez, Martha
dc.creatorTouzard-Romo, Francine
dc.creatorBrotherton, Amy
dc.creatorShah, Rajeev
dc.creatorCunha, Cheston B.
dc.creatorMylonakis, Eleftherios
dc.date.accessioned2020-10-01T16:39:39Z
dc.date.available2020-10-01T16:39:39Z
dc.date.created2020
dc.identifier.issn2213-7165spa
dc.identifier.otherhttp://dx.doi.org/10.1016/j.jgar.2020.07.018spa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/14094
dc.description.abstractAim: To assess the efficacy and safety of hydroxychloroquine with or without azithromycin) in hospitalized adult patients with COVID-19. Methods: We utilized a hospital based prospective data registry. The primary end point was to assess the impact of hydroxychloroquine with or without azithromycin, on outcome, length of hospitalization, and time to clinical improvement. We utilized treatment effects with inverse-probability-weighting and Cox proportional hazards models. All analyses accounted for age, gender, race, severity on admission, days from symptoms onset and chronic comorbidities. Results: 36 patients received hydroxychloroquine and were age- and sex-matched to 72 patients with COVID-19 who received supportive care. Compared to supportive care, the use of HCQ did not shorten the time to clinical improvement (+0.23 days; 95% CI: 1.8–2.3 days) nor did it shorten the duration of hospital stay (+0.91 days; 95% CI: 1.1–2.9 days). Additionally, HCQ did not decrease the risk of COVID-19 in-hospital death (aHR 1.67; 95% CI: 0.29–9.36). Finally, we observed a slight QTc prolongation from a baseline of 444 26 ms to 464 32 ms (meanSD) among patients receiving hydroxychloroquine with or without azithromycin. Conclusion: This study did not yield benefits from hydroxychloroquine use in patients with COVID-19 and monitoring for adverse events is warranted. Nevertheless, the treatment was safely studied under the guidance of an antimicrobial stewardship program.spa
dc.format.extent3 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherJournal of Global Antimicrobial Resistancespa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectCOVID-19spa
dc.subjectSARS-CoV-2spa
dc.subjectHydroxychloroquinespa
dc.subjectQTcspa
dc.subjectEfficacyspa
dc.subjectSafetyspa
dc.titleHydroxychloroquine use in hospitalised patients with COVID-19: An observational matched cohort studyspa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.rights.localAbierto (Texto Completo)spa
dc.identifier.doihttp://dx.doi.org/10.1016/j.jgar.2020.07.018spa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record